Insider Buying: Oncolytics Biotech (TSE:ONC) Insider Acquires C$13,830.48 in Stock

Oncolytics Biotech Inc. (TSE:ONC) insider Thomas Heineman bought 12,132 shares of the firm’s stock in a transaction dated Thursday, February 12th. The stock was purchased at an average price of C$1.14 per share, with a total value of C$13,830.48. Following the transaction, the insider owned 168,201 shares in the company, valued at approximately C$191,749.14. This represents a 7.77% increase in their position.

Oncolytics Biotech Price Performance

Shares of ONC opened at C$14.90 on Monday. Oncolytics Biotech Inc. has a 52 week low of C$0.44 and a 52 week high of C$2.08. The company has a current ratio of 2.99, a quick ratio of 8.86 and a debt-to-equity ratio of 11.75. The firm has a market cap of C$1.50 billion, a price-to-earnings ratio of -40.27 and a beta of 0.80. The stock has a 50 day moving average of C$14.90 and a 200-day moving average of C$13.19.

Oncolytics Biotech (TSE:ONC) last announced its quarterly earnings data on Wednesday, November 12th. The company reported C($0.14) earnings per share (EPS) for the quarter. As a group, analysts forecast that Oncolytics Biotech Inc. will post -0.41 EPS for the current year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.